In the Original Investigation titled “Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial,”1 the overall survival and metastatic-free survival curves in Figure 1B and Figure 1C were incorrectly drawn. This article was corrected online.
References
- 1.Conroy T, Castan F, Lopez A, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3839 [DOI] [PMC free article] [PubMed] [Google Scholar]